Combination of renal angioplasty and angiotensin-converting-enzyme inhibitor can reduce proteinuria in patients with bilateral renal artery disease

1Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.

Cite

CITATION STYLE

APA

Toda, H., Uchida, H. A., Nakamura, K., Takeuchi, H., Kinomura, M., Nakagawa, K., … Ito, H. (2019). Combination of renal angioplasty and angiotensin-converting-enzyme inhibitor can reduce proteinuria in patients with bilateral renal artery disease. Internal Medicine, 58(13), 1917–1922. https://doi.org/10.2169/internalmedicine.2076-18

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free